Filing Details

Accession Number:
0001493152-22-000113
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-03 16:15:50
Reporting Period:
2021-12-29
Accepted Time:
2022-01-03 16:15:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1641631 Beyond Air Inc. XAIR Surgical & Medical Instruments & Apparatus (3841) 473812456
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1702628 A. Steven Lisi C/O Beyond Air, Inc.
900 Stewart Avenue, Suite 301
Garden City NY 11530
Ceo And Chairman Of The Board Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-12-29 21,376 $9.53 1,150,111 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported on this Form 4 represent shares of common stock of Beyond Air, Inc. (the "Company") sold by the reporting person to cover tax withholding obligations in connection with the vesting of previously granted restricted stock units. The reporting person's sale of the Company's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 21,376 shares, with the reporting person's purchase of 25,000 shares of the Company's common stock at a weighted average price of $7.85 per share on August 13, 2021. The reporting person has paid to the Company, and the Company has received, $37,675, representing the full amount of the profit realized in connection with the short-swing transaction.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.70, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.